Stock PFE PFIZER, INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News Pfizer, Inc.

Equities

PFE

US7170811035

Market Closed - Nyse
Other stock markets
 04:01:19 2024-06-07 pm EDT 		5-day change 1st Jan Change
28.58 USD -0.76% Intraday chart for Pfizer, Inc. -0.28% -0.73%
12:02am US FDA expands GSK's RSV vaccine approval to adults aged 50 to 59 RE
Jun. 07 Pfizer's Paxlovid fails as 15-day treatment for long COVID, study finds RE

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
US FDA expands GSK's RSV vaccine approval to adults aged 50 to 59
RE
Pfizer's Paxlovid fails as 15-day treatment for long COVID, study finds
RE
COVID shots should target JN.1 variants in 2024-25 campaign, US FDA says
RE
AbbVie's tight grip on Humira market raises concerns about biosimilars
RE
FDA advisers urge targeting JN.1 strain in recipe for fall's COVID vaccines
AQ
Relay Therapeutics to Collaborate with Pfizer to Evaluate Breast Cancer Treatment
DJ
Relay Therapeutics to Collaborate With Pfizer to Evaluate Metastatic Breast Cancer Treatment
MT
Relay Therapeutics Announces Clinical Trial Collaboration with Pfizer to Evaluate Atirmociclib in Combination with RLY-2608
AQ
Pfizer : May Social Media Round-Up—Clinicals Trials Day, the TIME 100, and the Future of Cancer Care
PU
COVID shots for JN.1 variant neutralize newer strains, vaccine makers say
RE
Pfizer: article on Lyme vaccine in The Lancet
CF
Pfizer Partners with Abu Dhabi to Advance Research on Sickle Cell Disease
MT
Delhi HC's Ruling In Pfizer vs. Renovision; An Analysis
AQ
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
BU
Takeda Pharmaceutical, Pfizer Say Phase 3 Trial Assessing Blood Cancer Combination Therapy Met Co-Primary Endpoints
MT
COVID shots should target JN.1, KP.2 subvariants in 2024-25 campaign, US FDA staff says
RE
Pfizer: positive trial in large B-cell lymphoma
CF
Pfizer: promising trial in Hodgkin lymphoma
CF
GSK shares tumble 9% after 70,000 Zantac lawsuits allowed to proceed
RE
GSK Plans Appeal Against US Judge's Ruling on Jury Trials for Zantac Cases
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. PFE Stock
  4. News Pfizer, Inc.